Literature DB >> 22318430

PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

Katarzyna Karwacz1, Frederick Arce, Christopher Bricogne, Grazyna Kochan, David Escors.   

Abstract

PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data may provide an explanation for this apparent contradiction.

Entities:  

Year:  2012        PMID： 22318430      PMCID： PMC3272426          DOI： 10.4161/onci.1.1.17824

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism.

Authors:  E San José; A Borroto; F Niedergang; A Alcover; B Alarcón
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

2.  T-cell tolerance or function is determined by combinatorial costimulatory signals.

Authors:  Roza Nurieva; Sunil Thomas; Thang Nguyen; Natalia Martin-Orozco; Ying Wang; Murali-Krishna Kaja; Xue-Zhong Yu; Chen Dong
Journal:  EMBO J       Date:  2006-05-25       Impact factor: 11.598

Review 3.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

Authors:  Christian Blank; Thomas F Gajewski; Andreas Mackensen
Journal:  Cancer Immunol Immunother       Date:  2004-12-15       Impact factor: 6.968

4.  Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.

Authors:  Shari Pilon-Thomas; Amy Mackay; Nasreen Vohra; James J Mulé
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

5.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

Authors:  Yvette E Latchman; Spencer C Liang; Yin Wu; Tatyana Chernova; Raymond A Sobel; Martina Klemm; Vijay K Kuchroo; Gordon J Freeman; Arlene H Sharpe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.

Authors:  Hong Xin; Chunyan Zhang; Andreas Herrmann; Yan Du; Robert Figlin; Hua Yu
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

7.  Targeting dendritic cell signaling to regulate the response to immunization.

Authors:  David Escors; Luciene Lopes; Rongtuan Lin; John Hiscott; Shizuo Akira; Roger J Davis; Mary K Collins
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

8.  Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.

Authors:  Frederick Arce; Karine Breckpot; Holly Stephenson; Katarzyna Karwacz; Michael R Ehrenstein; Mary Collins; David Escors
Journal:  Arthritis Rheum       Date:  2011-01

9.  PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells.

Authors:  Katarzyna Karwacz; Christopher Bricogne; Douglas MacDonald; Frederick Arce; Clare L Bennett; Mary Collins; David Escors
Journal:  EMBO Mol Med       Date:  2011-08-10       Impact factor: 12.137

10.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307
  10 in total
  19 in total

Review 1.  PD-L1 in melanoma: facts and myths.

Authors:  Mario Mandalà; Barbara Merelli; Daniela Massi
Journal:  Melanoma Manag       Date:  2016-08-22

2.  Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Authors:  Blanca Homet Moreno; Jesse M Zaretsky; Angel Garcia-Diaz; Jennifer Tsoi; Giulia Parisi; Lidia Robert; Katrina Meeth; Abibatou Ndoye; Marcus Bosenberg; Ashani T Weeraratna; Thomas G Graeber; Begoña Comin-Anduix; Siwen Hu-Lieskovan; Antoni Ribas
Journal:  Cancer Immunol Res       Date:  2016-09-02       Impact factor: 11.151

3.  Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Authors:  Therese Liechtenstein; Noemi Perez-Janices; Idoia Blanco-Luquin; Cleo Goyvaerts; Julia Schwarze; Ines Dufait; Alessio Lanna; Mark De Ridder; David Guerrero-Setas; Karine Breckpot; David Escors
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

Review 4.  Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.

Authors:  Miren Zuazo; Maria Gato-Cañas; Noelia Llorente; María Ibañez-Vea; Hugo Arasanz; Grazyna Kochan; David Escors
Journal:  Ann Transl Med       Date:  2017-10

5.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05

6.  MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.

Authors:  Therese Liechtenstein; Ines Dufait; Alessio Lanna; Karine Breckpot; David Escors
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2012-09

7.  PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal.

Authors:  Therese Liechtenstein; Ines Dufait; Christopher Bricogne; Alessio Lanna; Joeri Pen; Karine Breckpot; David Escors
Journal:  J Clin Cell Immunol       Date:  2012-10-30

8.  Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression.

Authors:  Wanlu Lu; Libing Lu; Yun Feng; Jiao Chen; Yan Li; Xiangli Kong; Sixiu Chen; Xiaoyu Li; Qianming Chen; Ping Zhang
Journal:  Oncol Lett       Date:  2013-03-08       Impact factor: 2.967

9.  Retroviral and lentiviral vectors for the induction of immunological tolerance.

Authors:  Inès Dufait; Therese Liechtenstein; Alessio Lanna; Christopher Bricogne; Roberta Laranga; Antonella Padella; Karine Breckpot; David Escors
Journal:  Scientifica (Cairo)       Date:  2012-12

10.  Trial watch: Monoclonal antibodies in cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.